Status:
UNKNOWN
An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial
Lead Sponsor:
KEMRI-Wellcome Trust Collaborative Research Program
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Malaria
Eligibility:
All Genders
19-35 years
Brief Summary
Malaria is one of the leading causes of deaths in children below five years old. Despite antimalarial drugs and insecticide treated bed nets, the established means of treatment and protection, malaria...
Detailed Description
The RTS,S/AS01E candidate malaria vaccine is being developed for the routine immunization of infants and children living in malaria-endemic areas as part of the Expanded Program of Immunization (EPI)....
Eligibility Criteria
Inclusion
- Enrollment and vaccination in the RTS,S/AS01E clinical trial (NCT00380393)
- Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.
Exclusion
- Moving out of the study area, so that follow up is impractical.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2016
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00872963
Start Date
February 1 2009
End Date
August 1 2016
Last Update
December 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kemri Wellcome Trust Research Programme
Kilifi, Coast Province, Kenya, 80108